Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
复制标题
2022 年体外生命支持组织登记国际报告：100,000 名幸存者。
DOI：
10.1097/mat.0000000000002128
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Gómez,Ren
中科院分区：
文献类型：
--
作者：
Tonna,JosephE;Boonstra,PhilipS;MacLaren,Graeme;Paden,Matthew;Brodie,Daniel;Anders,Marc;Hoskote,Aparna;Ramanathan,Kollengode;Hyslop,Rob;Fanning,JeffreyJ;Rycus,Peter;Stead,Christine;Barrett,NicholasA;Mueller,Thomas;Gómez,Ren
披露：JET是体外生命支持组织（ELSO）注册委员会主席。PSB得到ELSO的工资支持。GM是ELSO的总裁。MP是ELSO的前任主席。DB接受LivaNova的研究支持和咨询。他是Abiomed、Xenios、Medtronic、Inspira和Cellenkos的医疗顾问委员会成员。他是ELSO的当选总统和国际ECMO网络（ECMONet）执行委员会主席，并为UpToDate撰稿。MA， AH和KR是ELSO科学监督委员会的前任联合主席。PR是ELSO的执行董事。CS是ELSO的首席执行官（CEO）。NAB是ELSO欧洲分会的主席。NAB是Xenios和Baxter的医疗顾问委员会成员。TM是ELSO的董事会成员。RDG是拉丁美洲组织拉丁美洲分会主席。PMK是ELSO西南亚和非洲分会的主席。JFF是ELSO亚太分会主席。PMAA是ELSO董事会的财务主管。PMAA由美国国防部PRMRP临床试验奖# W81XWH2210301，美国国立卫生研究院（R13HD104432）和FDA ucsf -斯坦福监管科学与创新卓越中心（U01FD004979/U01FD005978）资助。没有任何资金来源参与研究的设计或实施、数据的收集、管理、分析或解释，或手稿的准备、审查或批准。没有其他利益冲突的报道。RPB是ELSO的董事会成员，并接受国家心脏，肺和血液研究所（R01 HL153519）的资助。JET由美国国立卫生研究院/国家心脏、肺和血液研究所（K23 HL141596）的职业发展奖支持。本研究还得到了美国国立卫生研究院国家研究资源中心和国家促进转化科学中心的资助，资助项目为UL1TR002538（原5UL1TR001067-05、8UL1TR000105和UL1RR025764）。PMAA由美国国防部PRMRP临床试验奖# W81XWH2210301，美国国立卫生研究院（R13HD104432）和FDA ucsf -斯坦福监管科学与创新卓越中心（U01FD004979/U01FD005978）资助。没有任何资金来源参与研究的设计或实施、数据的收集、管理、分析或解释，或手稿的准备、审查或批准。
Disclosure: JET is the Chair of the Registry Committee of the Extracorporeal Life Support Organization (ELSO). PSB receives salary support from ELSO. GM is the President of ELSO. MP is the Immediate past President of ELSO. DB receives research support from and consults for LivaNova. He has been on the medical advisory boards for Abiomed, Xenios, Medtronic, Inspira, and Cellenkos. He is the President-elect of ELSO and the Chair of the Executive Committee of the International ECMO Network (ECMONet), and he writes for UpToDate. MA, AH, and KR are the Immediate Past Co-Chairs of the Scientific Oversight Committee of ELSO. PR is the Executive Director of ELSO. CS is the Chief Executive Officer (CEO) of ELSO. NAB is the President of European Chapter of ELSO. NAB has been on the medical advisory boards for Xenios and Baxter. TM is on the Board of Directors of ELSO. RDG is the President of the Latin-American Chapter of ELSO. PMK is the President of the South West Asia and Africa Chapter of ELSO. JFF is the President of Asia-Pacific Chapter of ELSO. PMAA is Treasurer of ELSO Board of Directors. PMAA is funded by US DoD PRMRP Clinical Trial Award# W81XWH2210301, NIH (R13HD104432) and FDA UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD004979/U01FD005978). None of the funding sources were involved in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript. No other conflicts of interest reported. RPB is a member of the Board of Directors for ELSO and receives funding from the National Heart, Lung, And Blood Institute (R01 HL153519).JET is supported by a Career Development Award from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23 HL141596). This study was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002538 (formerly 5UL1TR001067-05, 8UL1TR000105, and UL1RR025764). PMAA is funded by US DoD PRMRP Clinical Trial Award# W81XWH2210301, NIH (R13HD104432), and FDA UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD004979/U01FD005978). None of the funding sources were involved in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript.